Retatrutide, a new dual agonist of the GLP-1 target and glucose-dependent released polypeptide (GIP) target, is exhibiting promising results in preliminary human trials . Ongoing inquiry suggests that https://geniusbookmarks.com/story21350664/retatrutide-emerging-research-and-possible-medical-uses